The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial.
Fiche publication
Date publication
juin 2020
Journal
Trials
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BAGNARD Dominique, Pr MEYER Nicolas, Dr TRICARD Thibault, Pr DE SEZE Jérôme
Tous les auteurs :
Metzger-Peter K, Kremer LD, Edan G, Loureiro De Sousa P, Lamy J, Bagnard D, Mensah-Nyagan AG, Tricard T, Mathey G, Debouverie M, Berger E, Kerbrat A, Meyer N, De Seze J, Collongues N
Lien Pubmed
Résumé
Central nervous system damage in multiple sclerosis (MS) is responsible for serious deficiencies. Current therapies are focused on the treatment of inflammation; however, there is an urgent need for innovative therapies promoting neuroregeneration, particularly myelin repair. It is demonstrated that testosterone can act through neural androgen receptors and several clinical observations stimulated an interest in the potential protective effects of testosterone treatment for MS. Here, we sought to demonstrate the effects of a testosterone supplementation in testosterone-deficient men with relapsing-remitting MS.
Mots clés
Multiple sclerosis, Neuroprotection, Randomized controlled trial, Remyelination, Testosterone
Référence
Trials. 2020 Jun 29;21(1):591